Abstract P5-16-11: Residual cancer burden (RCB) as a strong prognosis factor in breast cáncer (BC) patients treated with neoadjuvant chemotherapy (NACT) based on carboplatin, doxorubicin and taxanes
Abstract:Purpose: Many pathologic response systems have been used since the arrival of NACT. The RCB is a standardized method, but not universally implemented (Symanns WF, et al. J Clin Oncol 2007). The main objective is to apply the RCB and check its prognostic value in patients treated with platinum-based NACT with a long follow up.
Methods: Patients diagnosed and treated with platinum based NACT are analyzed. They receive 4 cycles of carboplatin AUC 6 and doxorubicin 50 mg/m2, followed by either docet… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.